Titre : Feuillets embryonnaires

Feuillets embryonnaires : Questions médicales fréquentes

Termes MeSH sélectionnés :

Controlled Substances
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Feuillets embryonnaires : Questions médicales les plus fréquentes", "headline": "Feuillets embryonnaires : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Feuillets embryonnaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-24", "dateModified": "2025-04-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Feuillets embryonnaires" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Structures de l'embryon", "url": "https://questionsmedicales.fr/mesh/D004628", "about": { "@type": "MedicalCondition", "name": "Structures de l'embryon", "code": { "@type": "MedicalCode", "code": "D004628", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ectoderme", "alternateName": "Ectoderm", "url": "https://questionsmedicales.fr/mesh/D004475", "about": { "@type": "MedicalCondition", "name": "Ectoderme", "code": { "@type": "MedicalCode", "code": "D004475", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16.504.273" } } }, { "@type": "MedicalWebPage", "name": "Endoderme", "alternateName": "Endoderm", "url": "https://questionsmedicales.fr/mesh/D004707", "about": { "@type": "MedicalCondition", "name": "Endoderme", "code": { "@type": "MedicalCode", "code": "D004707", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16.504.407" } } }, { "@type": "MedicalWebPage", "name": "Mésoderme", "alternateName": "Mesoderm", "url": "https://questionsmedicales.fr/mesh/D008648", "about": { "@type": "MedicalCondition", "name": "Mésoderme", "code": { "@type": "MedicalCode", "code": "D008648", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16.504.660" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Péricytes", "alternateName": "Pericytes", "url": "https://questionsmedicales.fr/mesh/D020286", "about": { "@type": "MedicalCondition", "name": "Péricytes", "code": { "@type": "MedicalCode", "code": "D020286", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16.504.660.600" } } }, { "@type": "MedicalWebPage", "name": "Somites", "alternateName": "Somites", "url": "https://questionsmedicales.fr/mesh/D019170", "about": { "@type": "MedicalCondition", "name": "Somites", "code": { "@type": "MedicalCode", "code": "D019170", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16.504.660.750" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Feuillets embryonnaires", "alternateName": "Germ Layers", "code": { "@type": "MedicalCode", "code": "D005855", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Elizabeth R Gavis", "url": "https://questionsmedicales.fr/author/Elizabeth%20R%20Gavis", "affiliation": { "@type": "Organization", "name": "Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America." } }, { "@type": "Person", "name": "Bernard K van der Veer", "url": "https://questionsmedicales.fr/author/Bernard%20K%20van%20der%20Veer", "affiliation": { "@type": "Organization", "name": "Laboratory for Stem Cell and Developmental Epigenetics, Department of Development and Regeneration, Katholieke Universiteit Leuven, 3000 Leuven, Belgium." } }, { "@type": "Person", "name": "Kian Peng Koh", "url": "https://questionsmedicales.fr/author/Kian%20Peng%20Koh", "affiliation": { "@type": "Organization", "name": "Laboratory for Stem Cell and Developmental Epigenetics, Department of Development and Regeneration, Katholieke Universiteit Leuven, 3000 Leuven, Belgium." } }, { "@type": "Person", "name": "Ulrich Technau", "url": "https://questionsmedicales.fr/author/Ulrich%20Technau", "affiliation": { "@type": "Organization", "name": "Department for Molecular Evolution and Development, Centre of Organismal Systems Biology, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria ulrich.technau@univie.ac.at." } }, { "@type": "Person", "name": "Patrick P L Tam", "url": "https://questionsmedicales.fr/author/Patrick%20P%20L%20Tam", "affiliation": { "@type": "Organization", "name": "Embryology Research Unit, Children's Medical Research Institute, and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A Retrospective Cohort Study on Chronic Opioid Use After Geriatric Hip Fracture Surgery-Risk Factors, Trends, and Outcomes.", "datePublished": "2023-01-02", "url": "https://questionsmedicales.fr/article/36595589", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5435/JAAOS-D-22-00458" } }, { "@type": "ScholarlyArticle", "name": "Psychomodulatory substances: New legislative framework for control of psychoactive substances in Czechia.", "datePublished": "2024-10-09", "url": "https://questionsmedicales.fr/article/39388916", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugpo.2024.104603" } }, { "@type": "ScholarlyArticle", "name": "Fentanyl, heroin, and methamphetamine-based counterfeit pills sold at tourist-oriented pharmacies in Mexico: An ethnographic and drug checking study.", "datePublished": "2023-06-09", "url": "https://questionsmedicales.fr/article/37348270", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugalcdep.2023.110819" } }, { "@type": "ScholarlyArticle", "name": "The Effect of Online Prescription Drug Monitoring on Opioid Prescription Habits After Elective Single-level Lumbar Fusion.", "datePublished": "2022-08-09", "url": "https://questionsmedicales.fr/article/35947832", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5435/JAAOS-D-22-00433" } }, { "@type": "ScholarlyArticle", "name": "Diverting Data and Drugs: A Narrative Review of the Mallinckrodt Documents.", "datePublished": "2024-05-31", "url": "https://questionsmedicales.fr/article/38818605", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1017/jme.2024.60" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Structures de l'embryon", "item": "https://questionsmedicales.fr/mesh/D004628" }, { "@type": "ListItem", "position": 3, "name": "Feuillets embryonnaires", "item": "https://questionsmedicales.fr/mesh/D005855" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Feuillets embryonnaires - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Feuillets embryonnaires", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Feuillets embryonnaires", "description": "Comment identifier les feuillets embryonnaires ?\nQuels examens sont utilisés pour étudier les feuillets ?\nPeut-on détecter des anomalies des feuillets ?\nQuels signes indiquent des problèmes embryonnaires ?\nLes feuillets peuvent-ils être visualisés directement ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Controlled+Substances&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Feuillets embryonnaires", "description": "Quels symptômes sont liés aux anomalies des feuillets ?\nLes anomalies des feuillets affectent-elles le développement ?\nComment les anomalies se manifestent-elles ?\nLes symptômes varient-ils selon le feuillet affecté ?\nLes symptômes sont-ils toujours présents à la naissance ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Controlled+Substances&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Feuillets embryonnaires", "description": "Comment prévenir les anomalies des feuillets embryonnaires ?\nLe dépistage prénatal aide-t-il à prévenir les anomalies ?\nLes vaccinations sont-elles importantes pendant la grossesse ?\nLe stress maternel influence-t-il le développement embryonnaire ?\nLes antécédents familiaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Controlled+Substances&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Feuillets embryonnaires", "description": "Quels traitements existent pour les anomalies des feuillets ?\nPeut-on prévenir les anomalies des feuillets ?\nLes traitements sont-ils efficaces ?\nY a-t-il des traitements expérimentaux ?\nLes traitements nécessitent-ils un suivi ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Controlled+Substances&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Feuillets embryonnaires", "description": "Quelles complications peuvent survenir avec des anomalies des feuillets ?\nLes complications sont-elles toujours visibles à la naissance ?\nLes anomalies des feuillets augmentent-elles le risque de maladies ?\nLes complications peuvent-elles être traitées ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Controlled+Substances&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Feuillets embryonnaires", "description": "Quels sont les facteurs de risque pour les anomalies des feuillets ?\nL'exposition à des toxines influence-t-elle le développement ?\nLes maladies maternelles affectent-elles le fœtus ?\nLe mode de vie maternel joue-t-il un rôle ?\nLes traitements médicaux peuvent-ils influencer le développement ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Controlled+Substances&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les feuillets embryonnaires ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par l'observation des couches cellulaires lors de l'embryogenèse." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour étudier les feuillets ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'échographie et l'imagerie par résonance magnétique (IRM) sont couramment utilisés." } }, { "@type": "Question", "name": "Peut-on détecter des anomalies des feuillets ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies peuvent être détectées par des tests génétiques et des échographies." } }, { "@type": "Question", "name": "Quels signes indiquent des problèmes embryonnaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des malformations ou des retards de développement peuvent indiquer des problèmes." } }, { "@type": "Question", "name": "Les feuillets peuvent-ils être visualisés directement ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils sont généralement étudiés par des méthodes indirectes comme l'imagerie." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux anomalies des feuillets ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des malformations physiques et des troubles fonctionnels." } }, { "@type": "Question", "name": "Les anomalies des feuillets affectent-elles le développement ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des retards de croissance et des dysfonctionnements organiques." } }, { "@type": "Question", "name": "Comment les anomalies se manifestent-elles ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent se manifester par des malformations visibles ou des troubles internes." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le feuillet affecté ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque feuillet (ectoderme, mésoderme, endoderme) a des implications spécifiques." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents à la naissance ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, certaines anomalies peuvent se développer plus tard dans l'enfance." } }, { "@type": "Question", "name": "Comment prévenir les anomalies des feuillets embryonnaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée, l'évitement de substances nocives et des soins prénatals sont cruciaux." } }, { "@type": "Question", "name": "Le dépistage prénatal aide-t-il à prévenir les anomalies ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage permet d'identifier les risques et d'agir en conséquence." } }, { "@type": "Question", "name": "Les vaccinations sont-elles importantes pendant la grossesse ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines vaccinations protègent le fœtus contre des infections pouvant causer des anomalies." } }, { "@type": "Question", "name": "Le stress maternel influence-t-il le développement embryonnaire ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un stress élevé peut affecter le développement et augmenter le risque d'anomalies." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux d'anomalies peuvent augmenter le risque pour le fœtus." } }, { "@type": "Question", "name": "Quels traitements existent pour les anomalies des feuillets ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements varient de la chirurgie corrective à la thérapie génique selon l'anomalie." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies des feuillets ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Certaines anomalies peuvent être prévenues par une bonne nutrition et des soins prénatals." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité dépend de la nature et de la gravité de l'anomalie détectée." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des recherches sont en cours sur des thérapies innovantes pour certaines anomalies." } }, { "@type": "Question", "name": "Les traitements nécessitent-ils un suivi ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour évaluer l'évolution et ajuster les soins." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des anomalies des feuillets ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des malformations graves, des troubles fonctionnels et des décès néonatals." } }, { "@type": "Question", "name": "Les complications sont-elles toujours visibles à la naissance ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Non, certaines complications peuvent se manifester plus tard dans l'enfance." } }, { "@type": "Question", "name": "Les anomalies des feuillets augmentent-elles le risque de maladies ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent prédisposer à des maladies chroniques ou à des troubles du développement." } }, { "@type": "Question", "name": "Les complications peuvent-elles être traitées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées par des traitements médicaux ou chirurgicaux." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent avoir un impact significatif sur la qualité de vie de l'individu." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies des feuillets ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge maternel avancé, des antécédents familiaux et des infections." } }, { "@type": "Question", "name": "L'exposition à des toxines influence-t-elle le développement ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines environnementales peut augmenter le risque d'anomalies." } }, { "@type": "Question", "name": "Les maladies maternelles affectent-elles le fœtus ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies, comme le diabète, peuvent augmenter le risque d'anomalies congénitales." } }, { "@type": "Question", "name": "Le mode de vie maternel joue-t-il un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme, l'alcool et une mauvaise nutrition sont des facteurs de risque importants." } }, { "@type": "Question", "name": "Les traitements médicaux peuvent-ils influencer le développement ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent être tératogènes et affecter le développement embryonnaire." } } ] } ] }

Sources (10000 au total)

A Retrospective Cohort Study on Chronic Opioid Use After Geriatric Hip Fracture Surgery-Risk Factors, Trends, and Outcomes.

The purpose of this study is to identify the risk factors for prolonged opioid use after surgery in geriatric hip fracture patients and the effects of prolonged use on mortality and readmission rates.... An institutional registry was queried for all patients older than 65 years who underwent surgical treatment of a hip fracture between January 2016 and June 2017. Using the Controlled Substance Utiliza... Of 500 patients who underwent hip-fracture surgery during the study period, a total of 322 had complete Controlled Substance Utilization Review and Evaluation System data. 36.0% (116) were OE, and 64.... Opioid use in geriatric hip fracture patients is high both preoperatively and postoperatively. Opioid exposed patients and patients on antidepressants are more likely to continue opioids at 6 months. ... Level III....

Fentanyl, heroin, and methamphetamine-based counterfeit pills sold at tourist-oriented pharmacies in Mexico: An ethnographic and drug checking study.

Fentanyl- and methamphetamine-based counterfeit prescription drugs have driven escalating overdose death rates in the US, however their presence in Mexico has not been assessed. Our ethnographic team ... To characterize the availability of counterfeit and authentic controlled substances at pharmacies in Northern Mexico available to English-speaking tourists without a prescription.... We employed an iterative, exploratory, mixed methods design. Longitudinal ethnographic data was used to characterize tourist-oriented micro-neighborhoods and guide the selection of n=40 pharmacies in ... Of n=40 pharmacies, one or more of the requested controlled substances could be obtained with no prescription (as single pills or in bottles) at 28 (70.0%) and as single pills at 19 (47.5%). Counterfe... The availability of fentanyl-, heroin-, and methamphetamine-based counterfeit medications in tourist-oriented independent pharmacies in Northern Mexico represents a public health risk, and occurs in t...

The Effect of Online Prescription Drug Monitoring on Opioid Prescription Habits After Elective Single-level Lumbar Fusion.

The United States opioid epidemic is a well-documented crisis stemming from increased prescriptions of narcotics. Online prescription drug monitoring programs (PDMPs) are a potential resource to mitig... Patients who underwent a single-level lumbar fusion between August 27, 2017, and August 31, 2020, were identified and placed categorically into one of two cohorts: an "early adoption" cohort, Septembe... No significant difference was observed in preoperative opioid prescriptions between the early and late adoption cohorts. The late adoption group independently predicted decreased postoperative opioid ... PDMP implementation was associated with decreased postoperative opioid prescription patterns but not preoperative opioid prescribing behaviors.... 4....

Real or fake? Sourcing and marketing of non-prescribed benzodiazepines amongst two samples of people who regularly use illicit drugs in Australia.

There is concern around non-prescribed benzodiazepine use, particularly with increasing detections of counterfeit products containing high-risk novel compounds. The aims of this study were to investig... Data were collected from a sample of Australians who inject drugs or use ecstasy and/or other illicit stimulants on a monthly or more frequent basis, and who reported past 6-month use of non-prescribe... Amongst participants who injected drugs, 71% reported that their last non-prescribed benzodiazepines were diverted from a known/trusted prescription, compared to 59% of participants who used ecstasy/o... Most participants obtained substances sold as classic/registered benzodiazepines, mostly via diverted prescriptions, with a substantial minority potentially unaware of counterfeits circulating. While ...

Effect of Integrating Access to a Prescription Drug Monitoring Program Within the Electronic Health Record on the Frequency of Queries by Primary Care Clinicians: A Cluster Randomized Clinical Trial.

Tools that are directly integrated with the electronic health record (EHR) workflow can reduce the hassle cost of certain guideline-concordant practices, such as querying a prescription drug monitorin... To investigate the effect of integrating access to a PDMP within the EHR on the frequency of program queries by primary care clinicians.... The PRINCE (Prescribing Interventions for Chronic Pain Using the Electronic Health Record) randomized trial used a factorial cluster design at the clinic level in 43 primary care clinics in Minnesota.... Single sign-on access to the Minnesota PDMP was integrated into the EHR, allowing clinicians to query a patient's controlled substance prescription and dispensing history as recorded in the Minnesota ... Monthly PDMP query counts for primary care clinicians, overall and by modality (EHR-based, web-based, via a clinical delegate), adjusted for clinician characteristics, including type (physician, nurse... Of the 43 participating clinics with 309 clinicians, 21 clinics with 161 clinicians (102 [63.4%] women; 114 [70.8%] physicians; tenure, 10.6 [4.4] years) received the PDMP integration intervention. Ba... This cluster randomized clinical trial found that integrating access to the PDMP in the EHR increased PDMP-querying rates, suggesting that direct access reduced hassle costs and can dramatically impro... ClinicalTrials.gov Identifier: NCT04601506....

Prescription drug monitoring programs use mandates and prescription stimulant and depressant quantities.

While the mandate to check patients' prescription history in Prescription Drug Monitoring Program (PDMP) database before prescribing/dispensing controlled drugs has been shown to be an important tool ... Using data from Automated Reports and Consolidate Ordering System (ARCOS), we employed difference-in-differences design to estimate the association between PDMP use mandates and prescription stimulant... There was no evidence that limited PDMP use mandate was associated with a reduction in the prescription stimulant and depressant quantities. However, expansive PDMP use mandate that was non-specific t... Expansive PDMP use mandate was associated with a decline in prescription amphetamine quantity. Limited PDMP use mandate did not appear to change prescription stimulant and depressant quantities....

Review and inventory of 911 Good Samaritan Law Provisions in the United States.

911 Good Samaritan Laws (GSLs) confer limited legal immunity to bystanders in possession of controlled substances who report emergency overdoses. While these laws may decrease opioid overdose mortalit... We identified all state GSLs and their legislative history, characterizing features into four categories using a novel framework: breadth of protected activities, burden placed on Good Samaritans, str... GSLs vary substantially across states and time. Protections depend on the quantity of substances involved and may extend to the person experiencing the overdose or persons reporting their own overdose... States offer Good Samaritans substantially different protections even when the statutes confer nominally comparable immunities. Accommodating this heterogeneity will enhance the validity of future stu...